Avastin, Lucentis equal in five-year AMD study

In an Avastin bevacizumab or Lucentis ranibizumab . The researchers highlighted the "remarkable" maintenance of visual acuity relative to outcomes prior to the development of anti-VEGF therapies such as Avastin and Lucentis.

Roche (SIX:ROG; OTCQX:RHHBY)

Read the full 351 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE